Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05625633 · ClinicalTrials.gov registry record · Phase 2
Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts
A Phase 2 study of Warts, sponsored by Western Institute for Veterans Research.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 2
- Study locations
NCT05625633 is a Phase 2 study of Warts that is actively recruiting participants, run by Western Institute for Veterans Research. The registered enrollment target is 120 participants, below the 205-participant average among 7 other Warts trials with a reported enrollment target (41% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT05625633, a Phase 2 study of Warts, is actively recruiting participants, sponsored by Western Institute for Veterans Research.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 2
- Study locations
Study Summary
This double-blinded clinical trial randomly assigns participants with refractory cutaneous warts to receive either treatment with the human papillomavirus (HPV) vaccine or a placebo to assess the efficacy of HPV vaccination for the treatment of refractory cutaneous warts.
Conditions Studied
Interventions
- OTHER Normal Saline
- BIOLOGICAL Human Papillomavirus 9-valent Vaccine, Recombinant
Study Locations (2)
Utah
- University of Utah Midvalley Health Center - Salt Lake City
- VA Salt Lake City Health Care System - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2024-03-25 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05625633
The ClinicalTrials.gov registry entry for NCT05625633 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 205-participant average among 7 other Warts trials with a reported enrollment target (41% lower). The listed sponsor is Western Institute for Veterans Research, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Warts appearing as the primary indexed condition, and to 2 interventions - of which Normal Saline is the first listed.
NCT05625633 reports 2 study locations spanning 1 distinct geographic area - top geographies include Utah.
Frequently Asked Questions
What is clinical trial NCT05625633 about?
NCT05625633 is a clinical study titled "Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts". This double-blinded clinical trial randomly assigns participants with refractory cutaneous warts to receive either treatment with the human papillomavirus (HPV) vaccine or a placebo to assess the efficacy of HPV vaccination for the treatment of refractory cutaneous warts.
What is the current status of trial NCT05625633?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2024-03-25. Estimated completion is 2026-12.
What conditions does trial NCT05625633 study?
This clinical trial studies the following conditions: Warts.
What interventions are being tested in trial NCT05625633?
The interventions under investigation include: Normal Saline (OTHER), Human Papillomavirus 9-valent Vaccine, Recombinant (BIOLOGICAL).
Who is sponsoring clinical trial NCT05625633?
This trial is sponsored by Western Institute for Veterans Research, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05625633 being conducted?
This trial has 2 study locations across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Warts
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Candin Safety & Efficacy Study for the Treatment of Warts
COMPLETED · Phase 2
-
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
RECRUITING · Phase 1
-
Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia
RECRUITING
-
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)
RECRUITING · Phase 3
-
Microwave Treatment of Common and Plantar Warts
ACTIVE NOT RECRUITING · NA
-
Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.